Skip to content

Red Ginseng for the Prevention of TC/TP chemotherapy-induced myelosuppression in Ovarian Cancer Patients

Red Ginseng for the Prevention of TC/TP chemotherapy-induced myelosuppression in Ovarian Cancer Patients

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044696
Enrollment
Unknown
Registered
2021-03-25
Start date
2021-04-01
Completion date
Unknown
Last updated
2021-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myelosuppression

Interventions

Sponsors

The University Branch of Guangdong Province Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Patients, between 30 and 70 years of age, diagnosed with ovarian cancer; 2.Patients who have not received chemotherapy and who will undergo TC/TP chemotherapy; 3.Patients who meet the diagnostic criteria of qi deficiency in TCM; 4.Patients who voluntarily sign the informed consent to this trial and consent to participate in all visits as required.

Exclusion criteria

Exclusion criteria: 1.Patients who have hematologic diseases, such as aplastic anemia, acute leukemia, radiation sickness, immune thrombocytopenic purpura, bone marrow invasion of cancers and hypersplenism; 2.Patients who have to use drugs which may cause changes in the blood cells, such as sulfonamides, certain non-steroidal anti-inflammatory drugs; 3.Patients who allergy to multiple drugs; 4.Patients with expected survival time less than 3 months; 5.Patients with serious primary diseases, such as heart, brain, liver and hematopoietic system diseases; 6.Uncooperative patients, such as patients with mental disorder; 7.Patients who are participating in other clinical trials or have participated in other clinical trials within 3 months; 8.Patients have diseases or other conditions that will reduce the possibility of enrollment or complicate the enrollment.

Design outcomes

Primary

MeasureTime frame
complete blood count;

Secondary

MeasureTime frame
Use of drugs to improve bone marrow hematopoiesis;TCM Syndrome;

Countries

China

Contacts

Public ContactJing Xiao

The Second clinical college of Guangzhou University of Chinese Medicine

xiaojingson_2004@126.com+86 13556148318

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026